ANAKA PHARMA

Serial Number 99123382
688

Registration Progress

Application Filed
Apr 7, 2025
Under Examination
Jan 20, 2026
Approved for Publication
Nov 25, 2025
Published for Opposition
Nov 25, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Jul 20, 2026 169 days

Trademark Image

ANAKA PHARMA

Basic Information

Serial Number
99123382
Filing Date
April 7, 2025
Published for Opposition
November 25, 2025
Drawing Code
3

Status Summary

Current Status
Active
Status Code
688
Status Date
Jan 20, 2026
Application
Pending
Classes
005 042

Rights Holder

Anaka Pharmaceuticals, Inc.

03
Address
21 Seaborn Place
Lexington, MA 02420

Ownership History

Anaka Pharmaceuticals, Inc.

Original Applicant
03
Lexington, MA

Anaka Pharmaceuticals, Inc.

Owner at Publication
03
Lexington, MA

Legal Representation

Attorney
Laura K. Johnson

USPTO Deadlines

Next Deadline
169 days remaining
NOA E-Mailed - SOU Required
Due Date
July 20, 2026
Extension Available
Until January 20, 2027

Application History

16 events
Date Code Type Description Documents
Jan 20, 2026 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 25, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 25, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 19, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 23, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 22, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 22, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 22, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 4, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 4, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 4, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 3, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 18, 2025 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Aug 18, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 7, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Apr 7, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Small molecule therapeutic pharmaceuticals for the treatment of neurodevelopmental disorders, namely, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, and Down syndrome
Class 042
Pharmaceutical research and development for neurodevelopment disorders

Additional Information

Design Mark
The mark consists of figures representing molecular models positioned at the top left of the wording "anaka pharma." The first molecular model consists of three purple circles of varying sizes connected by lines. The second model includes three blue circles of different sizes, also connected by lines. The third model has two orange circles of varying sizes connected by a line, with a small purple circle positioned above the figure. The wording "anaka" is in stylized, bold, lower-case black letters, and the wording "pharma" is in smaller, stylized, bold, and thinner lower-case black letters beneath it. The white in the mark is background and is not part of the mark.
Color Claim
The color(s) purple, blue, orange, and black is/are claimed as a feature of the mark.

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
PHARMA